VEGF-B taken to our hearts: Specific effect of VEGF-B in myocardial ischemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 9, 2008, Pages 1575-1576

  Claesson Welsh, Lena ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARAN SULFATE; NEUROPILIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; EDITORIAL; HEART MUSCLE ISCHEMIA; INFLAMMATORY CELL; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RECEPTOR BINDING; ANIMAL; CORONARY BLOOD VESSEL; HEART MUSCLE; HUMAN; METABOLISM; NOTE; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CORONARY VESSELS; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR B;

EID: 51649130078     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.170878     Document Type: Editorial

References (17)

1. Olofsson B, Pajusola K, Kaipainen A, von Euler G, loukov V, Saksela O, Orpana A, Pettersson RF, Alitalo K, Eriksson. U. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U. S. A. 1996;93:2576-2581.
2. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359-371.
3. Li X, Tjwa M, Van Hove I, Enholm B, Neven E, Paavonen K, Jeltsch M, Diez Juan T, Sievers RE, Chorianopoulos E, Wada H, Vanwildemeersch M, Noel A, Foidart JM, Springer ML, von Degenfeld G, Dewerchin M, Blau HM, Alitalo K, Eriksson U, Carmeliet P, Moons L. Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol. 2008;28: 1614-1620.
4. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007;18:502-508.
5. Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005;69 Suppl 3:11-16.
6. Willett CG, Duda DG, Czito BG, Bendell JC, Clark. JW, Jain RK. Targeted therapy in rectal cancer. Oncology (Williston Park). 2007;21: 1055-1065; discussion. 1065, 1070, 1075 passim.
7. Saharinen P, Tammela T, Karkkainen MJ, Alitalo K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol. 2004;25:387-395.
8. Haiko P, Makinen T, Keskitalo S, Taipale J, Karkkainen MJ, Baldwin ME, Stacker SA, Achen MG, Alitalo K. Deletion of VEGF-C and VEGF-D is not equivalent to VEGFR-3-null in mouse embryos. Mol Cell Biol. in press.
9. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothe-lium. Nature. 1995;376:66-70.
10. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U. S. A. 1998;95:9349-9354.
11. Wallgard E, Larsson E, He L, Hellstrom M, Armulik A, Nisancioglu MH, Genove G, Lindahl P, Betsholtz C. Identification of a core set of 58 gene transcripts with broad, and specific expression in the microvasculature. Arterioscler Thromb Vasc Biol, In press.
12. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell. 2007;11:539-554.
13. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, Stassen JM, Dewerchin M, Collen D, Carmeliet P. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007;131:463-475.
14. Carmeliet P, Moons L, Luttun A, Vincenti V, Compemolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Chamock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persko MG. Synergism, between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7:575-583.
15. Hiratsuka S, Maru Y, Okada A,Sciki M, Noda T, Shibuya M. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. 2001;61: 1207-1213.
16. Bellomo D, Headrick JP, Silins GU, Paterson. CA, Thomas PS, Gartside M, Mould. A, Cahill MM, Tonks ID, Grimmond SM, Townson S, Wells C, Little M, Cummings MC, Hayward NK, Kay GF. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from, cardiac ischemia. Circ Res. 2000;86:e29-e35.
17. Aase K, von Euler G, Li X, Ponten A, Thoren P, Cao R, Cao Y, Olofsson. B, Gebre-Medhin S, Pekny M, Alitalo K, Betsholtz C, Eriksson U. Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. Circulation. 2001;104:358-364.